Prostate Cancer cT2bN0M0, High-Risk, Gleason 4+3=7 (Grade Group 3), PSA 69.7 ng/mL

Risk Classification - Why This Is "High Risk"

• Clinical stage T3a or above
• Grade Group 4 or 5 (Gleason ≥8)
• PSA >20 ng/mL

• cT2b - bilateral disease, confined to prostate (not T3a/T3b)
• Gleason 4+3=7 = Grade Group 3 - this is unfavorable intermediate risk by Gleason alone (GG3 does NOT qualify as high-risk by grade)
• PSA 69.7 ng/mL = high-risk (PSA >20 ng/mL is met; note PSA >40 also met, which is a very-high-risk feature per NCCN 2025)

Treatment Options with Evidence

Option 1: External Beam Radiotherapy (EBRT) + Long-Term ADT (± Abiraterone)

• IMRT/VMAT with image-guided RT (IGRT) to prostate (74-81 Gy or equivalent hypofractionated schedule)
• Pelvic nodal irradiation (to common/external/internal iliac nodes) - recommended for high-risk
• Long-term ADT for 2-3 years (GnRH agonist/antagonist)
• Addition of abiraterone acetate + prednisolone for 2 years in patients with ≥2 high-risk features (PSA ≥40 ng/mL is one)

1. STAMPEDE trial - meta-analysis (Attard et al., Lancet 2022, PMID 34953525): This landmark meta-analysis of two Phase 3 RCTs (n=1,974) showed that adding abiraterone/prednisolone to ADT + radiotherapy in high-risk non-metastatic PCa produced a metastasis-free survival HR of 0.53 (p<0.0001) and significantly improved overall survival vs ADT + RT alone. The median PSA in STAMPEDE was 34 ng/mL, making this patient directly applicable. The EAU 2025 guidelines give a Strong recommendation for abiraterone + 2-year ADT + IMRT/IGRT in patients with ≥2 high-risk features (PSA ≥40 ng/mL qualifies).
2. ADT Duration Meta-Analysis (Zaorsky et al., JAMA Oncol 2026, PMID 41264309): Individual patient data meta-analysis of 13 Phase 3 RCTs (n=10,266) with median follow-up 11.3 years. For high-risk and very-high-risk patients, longer ADT duration had undefined optimal ceiling - benefits continued to accrue beyond 9-12 months. Standard 18-36 months ADT for high-risk is well-supported. Near-linear increase in other-cause mortality with very long ADT means 2-3 years is the sweet spot. - Harrison's Principles, 22E (2025), p.743
3. EAU-EANM-ESTRO 2024 Guidelines (Cornford et al., Eur Urol 2024, PMID 38614820): Multi-society guideline explicitly recommends:
   • "Offer long-term ADT for at least two years" (Strong recommendation)
   • "Offer IMRT/VMAT + IGRT + long-term ADT + 2 years of abiraterone to cN0M0 patients with ≥2 high-risk factors (cT3-4, Gleason ≥8 OR PSA ≥40 ng/mL)" (Strong recommendation)

Option 2: Radical Prostatectomy (RP) + Extended Pelvic Lymph Node Dissection (ePLND)

• Robot-assisted or open radical prostatectomy
• Extended PLND (external iliac, internal iliac, obturator, and ideally common iliac nodes)
• Adjuvant or salvage RT + ADT postoperatively if adverse pathologic features present
• Neoadjuvant ADT alone is NOT standard (no OS benefit in trials) - Harrison's Principles, 22E (2025)

1. NRG/RTOG 0521 vs CALGB 90203 (Roy et al., Eur Urol Oncol 2026, PMID 40683825): This 2026 RCT-level comparison of RT-based (n=557, RT + 24 months ADT ± docetaxel) vs RP-based (n=733, RP ± neoadjuvant docetaxel/ADT + postoperative therapy) treatment in high-risk PCa found that radiotherapy-based treatment resulted in significantly lower 8-year distant metastasis (15% vs 22%, adjusted sHR 0.58, p=0.001). Deaths after distant metastasis were equivalent. This is the most contemporary head-to-head data and suggests RT may offer superior metastasis control in high-risk disease.
2. PSA control rates are similar between high-dose RT and contemporary surgery series. The few Phase 3 RCTs comparing RT vs RP have shown no significant oncologic differences overall, but toxicity profiles differ. - Smith & Tanagho General Urology, 19th Ed

Option 3: Combined EBRT + Brachytherapy Boost + ADT

Option 4: Docetaxel Addition (Intensified Systemic Therapy)

• Very-high-risk disease (PSA >40 ng/mL meets one criterion)
• Part of peri-operative strategy with RP (CALGB 90203 arm used 6 cycles neoadjuvant docetaxel)
• As intensification alongside RT + ADT in select cases

What Is NOT Recommended

• Active surveillance: Absolutely inappropriate. PSA 69.7 and Gleason 4+3 preclude this.
• ADT monotherapy alone: Only for patients unfit for local treatment or palliative intent. Inferior to combined modality therapy for potential cure.
• Neoadjuvant ADT before RP: Multiple large trials show no improvement in clinically relevant outcomes; not standard of care. - Harrison's Principles, 22E (2025)
• Whole gland focal therapy (HIFU, cryotherapy): EAU 2025 states "Do not offer whole gland treatment or focal treatment" for high-risk disease (Strong recommendation).

Restaging Before Definitive Treatment

• PSMA PET-CT is mandatory (EAU 2024/2025: Strong recommendation). This PSA level substantially raises the probability of nodal or occult metastatic disease that conventional CT + bone scan will miss. If PSMA PET-CT unavailable, do CT abdomen/pelvis + bone scan.
• If N1 on PSMA PET-CT: Treatment intensifies - IMRT to prostate + pelvis + long-term ADT + 2-year abiraterone (EAU 2025 Strong recommendation).
• If M1 (oligometastatic): Different pathway - hormone-sensitive metastatic disease protocols apply (ADT + novel hormonal agents ± docetaxel).

Summary Table

Clinical Bottom Line for This Patient

IMRT/VMAT + IGRT to prostate and pelvis + 2-3 years of ADT (GnRH agonist/antagonist) + abiraterone acetate/prednisolone for 2 years

• EAU 2024 Guidelines - Cornford et al., Eur Urol 2024 (PMID 38614820)
• STAMPEDE meta-analysis - Attard et al., Lancet 2022 (PMID 34953525)
• ADT duration meta-analysis - Zaorsky et al., JAMA Oncol 2026 (PMID 41264309)
• RT vs surgery RCT - Roy et al., Eur Urol Oncol 2026 (PMID 40683825)
• Harrison's Principles of Internal Medicine 22E (2025), pp. 743-744
• Smith & Tanagho's General Urology, 19th Ed

SBRT and Pelvic (Whole Pelvis / Nodal) RT for cT2bN0M0 High-Risk Prostate Cancer

1. SBRT (Ultra-Hypofractionation) for the Prostate

What It Is

Is SBRT Appropriate in This High-Risk Patient?

Key Evidence

• Largest randomised trial comparing SBRT (36.25 Gy/5 fractions) vs moderate hypofractionated IMRT (60 Gy/20 fractions) in intermediate and high-risk patients (T1-T3a, Gleason 7-8, PSA 10-30)
• n=1,208 patients; 6 months ADT mandated in both arms
• Acute GU toxicity Grade ≥2: 27% MHRT vs 28% SBRT (p=0.89) - non-inferior
• Acute GI toxicity Grade ≥2 slightly higher with SBRT (17% vs 10% CTCAE), but Grade 3 events <1% in both arms
• Efficacy (freedom from biochemical/clinical failure) data not yet mature - trial still in follow-up
• Conclusion: SBRT is safe and feasible in higher-risk patients but long-term oncologic data are still awaited

• 100 patients with unfavorable intermediate and high-risk prostate cancer
• Randomised to pelvic CF-EBRT (45-46 Gy/23-25 fractions) followed by either:
  • CF-EBRT boost (32-34 Gy/15-17 fractions) OR
  • SBRT boost (19.5-21 Gy in 3 weekly fractions)
• No significant difference in QoL (EPIC scores), IPSS, or acute toxicity (OR 0.90)
• Biochemical failure <5% in both groups at mean 18.5 months follow-up
• This is directly relevant - using SBRT as a prostate boost after conventional pelvic EBRT is a practical hybrid approach for high-risk patients who still need pelvic nodal coverage with standard fractionation

Current Guideline Position on SBRT for High-Risk Disease

• NCCN 2025/2026: Lists SBRT (ultra-hypofractionation) as an acceptable option for high-risk disease, with the caveat that moderate hypofractionation is preferred when pelvic nodal irradiation is planned (because simultaneous ultra-hypo to pelvis is less well established)
• ASTRO/ASCO/AUA 2018 guideline: Moderate hypofractionation is a strong recommendation for high-risk where pelvic nodes will be treated; ultra-hypofractionation is conditionally acceptable where nodes are not irradiated
• EAU 2024/2025: Does not currently give SBRT a specific Strong recommendation for high-risk; moderate hypofractionation or conventional fractionation are the stated standard when combining with ADT + abiraterone

2. Whole Pelvis / Pelvic Nodal RT (Elective Nodal Irradiation - ENI)

Why This Is Important for This Patient

Estimated nodal risk = (2/3 × PSA) + (10 × [GS - 6]) = (2/3 × 69.7) + (10 × [7-6]) = 46.5% + 10% = ~56% estimated probability of nodal involvement

What Pelvic RT Involves

• Conventional dose to pelvis: 45-50 Gy/25 fractions (1.8-2 Gy/fraction)
• Moderate hypofractionation: 45-48 Gy/20-25 fractions (simultaneous integrated boost [SIB] possible)
• Ultra-hypofractionation (SBRT-like) to pelvis: 25 Gy in 5 fractions - the "whole pelvis SBRT" or ultra-hypo pelvic nodal irradiation protocol

Ultra-Hypofractionated Pelvic Nodal Irradiation - The Emerging Data

• 7 studies, 417 patients; median pelvic dose 25 Gy/5 fractions; median prostate dose 40 Gy/5 fractions; all received ADT (median 18 months)
• Late Grade ≥2 GI toxicity: 13% (95% CI 5-21%)
• Late Grade ≥2 GU toxicity: 29% (95% CI 17-42%)
• Conclusion: "Ultra-hypofractionated pelvic nodal irradiation appears to be a safe approach"

• Ongoing multi-institutional non-inferiority Phase 3 trial comparing ultra-hypo pelvic irradiation vs conventionally fractionated IMRT + HDR brachytherapy in prostate cancer
• Interim analysis published 2026 - full results pending

Does Elective Pelvic RT Actually Improve Outcomes?

• Several Phase 3 trials (RTOG 9413, RTOG 0924) have shown benefit of whole pelvis RT over prostate-only RT in patients with nodal risk >15%, particularly when combined with ADT
• The issue has been whether the toxicity of pelvic RT outweighs the benefit - modern IMRT/VMAT with IGRT has substantially reduced GI/GU toxicity compared to older 3D conformal techniques
• EAU 2024 states pelvic RT is recommended in N1 disease (strong); for cN0 with high nodal risk it is an option at experienced centres

Practical Fractionation Protocols - Summary for This Patient

Why the Pelvic RT Is Especially Important Here

1. Even with a negative PSMA PET-CT, sub-radiological nodal disease is very likely
2. Treating the pelvis addresses micrometastatic nodal disease that imaging cannot detect
3. STAMPEDE (which showed the abiraterone benefit) mandated pelvic RT for most patients - so the intensified regimen should include nodal coverage
4. If PSMA PET-CT shows N1 disease, EAU gives a Strong recommendation for prostate + pelvic RT + long-term ADT + 2 years abiraterone

Revised Complete Radiotherapy Strategy for This Patient

IMRT/VMAT + IGRT to prostate and pelvis (moderate hypofractionation: 60 Gy prostate / 48 Gy nodes in 20 fractions, or conventional fractionation if SBRT pelvic coverage is not available) + long-term ADT 2-3 years + abiraterone/prednisolone 2 years

Prostate 40 Gy / Pelvis 25 Gy in 5 fractions (SHARP protocol) + ADT 18-24 months - feasible at centres with SBRT expertise and MRI-guided adaptive RT capability; increasingly supported by prospective data but not yet a guideline-endorsed first choice

• PACE-C Phase 3 RCT - Tree et al., Lancet Oncol 2025 (PMID 40517778)
• Ultra-hypo pelvic nodal meta-analysis - Mohamad et al., Int J Radiat Oncol Biol Phys 2024 (PMID 37863241)
• SBRT boost Phase 2 RCT - Gouveia et al., Prostate 2025 (PMID 40287937)
• Smith & Tanagho General Urology, 19th Ed - Section C: Stereotactic Radiotherapy

The Roach Formula: Limitations, Why It Overestimates, and How to Use It Correctly

The Problem - Why It Overestimates

1. Derived from an Era of PSA Overestimation

2. PSA as a Linear Variable

3. Uses Only Two Variables

• Clinical T stage
• Number/percentage of positive biopsy cores
• Perineural invasion
• Lymphovascular invasion
• MRI findings (extracapsular extension, seminal vesicle invasion)

4. Does Not Use Grade Group (ISUP) System

5. AUC of Only 0.781

So How Should We Actually Use It?

The Correct Approach: Roach as a Screening Tool, Not a Decision Tool

If Roach formula risk is >15%, consider that pelvic nodal coverage is warranted. But never use the exact percentage as a literal probability of nodal disease.

Step 1: Use a More Accurate Nomogram to Refine the Estimate

Step 2: Integrate mpMRI Findings

• Extracapsular extension (ECE) on MRI increases nodal risk
• Seminal vesicle invasion on MRI (T3b equivalent) substantially raises nodal risk
• The Draulans et al. 2020 model (J Urol) adds mpMRI staging to the Briganti nomogram and improves nodal risk prediction further

Step 3: PSMA PET-CT - The Modern Standard

• PSMA PET positive nodes (N1): Treat as N1 disease. Pelvic RT + ADT + abiraterone. The formula is superseded.
• PSMA PET negative (N0): This is where the formula still matters. PSMA PET has ~40-84% sensitivity for nodal metastases depending on the study - meaning it misses a significant proportion of microscopic nodal disease. The Roach / Briganti estimate then quantifies the residual probability of undetected nodal disease and guides the decision to irradiate nodes prophylactically.

PSMA PET and the Roach formula / Briganti nomogram are complementary, not competing tools. PSMA PET detects macroscopic nodal disease; the nomogram estimates the probability of microscopic disease PSMA cannot see.

Applied to This Patient (PSA 69.7, cT2b, GS 4+3=7)

How Recent Studies Are Assessing Elective Nodal Risk in Prostate Cancer

1. The Landmark RCT That Shifted the Field: POP-RT Trial

• Enrolled only high-risk/very-high-risk cN0 patients with nodal risk ≥20% (by Roach formula)
• All received IGRT + IMRT (not older 3D-CRT) - a critical distinction from failed older trials
• Pelvic field included common iliac nodes (correcting the target volume error of prior trials)
• Minimum 2 years ADT in both arms

• 5-year BFFS: 95.0% (WPRT) vs 81.2% (PORT) - HR 0.23, p<0.0001
• 5-year DFS: 89.5% vs 77.2% - HR 0.40, p=0.002
• 5-year distant MFS: 95.9% vs 89.2% - HR 0.35, p=0.01
• OS: no difference (92.5% vs 90.8%) - follow-up too short for OS signal
• Late urinary toxicity: similar grade 3 (~5%) in both arms; QoL scores equivalent

2. The Contrasting Negative Trial: NRG/RTOG 0924

• 10-year OS: 68% in both arms (HR 1.01, p=0.54)
• Biochemical failure: slightly lower in whole-pelvis arm, but no OS benefit
• Conclusion: No benefit from whole-pelvis RT in this lower-risk group

3. Modern Risk-Stratification Methods Beyond the Roach Formula

A. Briganti Nomogram (2012/2019 Updated Versions)

• PSA
• Clinical T stage
• ISUP grade group (not just Gleason sum)
• Number and percentage of positive biopsy cores
• Presence of perineural invasion

B. MSKCC Nomogram (Memorial Sloan Kettering)

C. mpMRI-Augmented Nodal Risk Models

• Extent of extracapsular extension on MRI
• Seminal vesicle invasion (upgrading T stage beyond clinical exam)
• This "add-on" model improved nodal risk prediction accuracy beyond the standard Briganti nomogram

4. PSMA PET-CT as a Risk Stratification Tool - and Its Limits

• Detects macroscopic nodal metastases with 80-84% sensitivity and ~95% specificity (aggregate data)
• Upgrades ~20-30% of high-risk cN0 patients to N1 status, directly changing treatment volumes
• Identifies extrapelvic nodal disease (para-aortic, Virchow) that changes intent from curative to palliative

• Sensitivity for nodes <5mm is only ~40% (OSPREY trial data, AUA/ASTRO 2026 guideline)
• In patients with ≥40% Roach-estimated risk, roughly half of actual nodal metastases will be missed by PSMA PET
• This is precisely why nomogram-based risk estimation remains indispensable even after a negative PSMA PET

• PSMA PET positive (N1): Pelvic RT mandatory
• PSMA PET negative (cN0) but high clinical risk (cT3a, GS ≥8, PSA ≥20 ng/mL): ENI still offered - this is the POP-RT population
• PSMA PET negative, lower risk (RTOG 0924 type): Prostate-only RT acceptable

5. Patterns-of-Failure Studies to Refine Contouring

• 68 patients who failed after PORT (many from POP-RT control arm) underwent PSMA PET at relapse
• Regional nodal failure in 46% of patients - confirming the ENI rationale
• 64% of nodal failures involved the common iliac region - explaining why older trials that omitted common iliac failed to show benefit
• The caudal-most nodal recurrence was 20mm above pubic symphysis - informing where the lower contouring border should sit

6. Genomic Classifiers - The Emerging Frontier

• Decipher scores obtained from ~700 post-prostatectomy patients enrolled in SPPORT (which compared prostate bed RT alone vs + ADT vs + pelvic RT + ADT)
• High Decipher score patients derived more benefit from the addition of pelvic RT + ADT than low-score patients
• This is proof-of-concept that genomic classifiers can identify who will benefit from ENI, independently of PSA, Gleason, and stage

• Prospectively testing whether Decipher score can guide treatment intensification (including pelvic RT) vs de-intensification in localised disease
• These represent the next generation of "biology-first" ENI selection

7. The Whole Framework - How Risk Is Now Assessed (2025 Standard)

Step 1: Clinical risk classification
         (NCCN/EAU: T stage, GS grade group, PSA)
         → Does patient meet high-risk criteria?

Step 2: Nodal risk quantification
         Briganti nomogram (preferred) or MSKCC nomogram
         + mpMRI (extracapsular extension, seminal vesicle invasion)
         → Calculate probability of nodal involvement

Step 3: Modern imaging
         PSMA PET-CT (Strong recommendation, EAU 2024 for high-risk)
         → Positive: confirms N1, guide boost volumes
         → Negative: use residual probability from Step 2
                      (PSMA misses ~40-60% microscopic disease)

Step 4: Genomic classifier (where available)
         Decipher biopsy score
         → High score: favour ENI even if imaging negative
         → Low score: may support prostate-only approach

Step 5: Patient risk profile for ENI
         ENI clearly beneficial: POP-RT type (cT3a/b, GS ≥8, PSA ≥20)
         ENI not clearly beneficial: RTOG 0924 type (unfav. intermediate/
                                     favourable high-risk, PSA <50, cT1-2b)
         ENI mandatory: PSMA-confirmed N1

Applied to Your Patient (PSA 69.7, cT2b, GS 4+3=7)

• POP-RT RCT - Murthy et al., J Clin Oncol 2021 (PMID 33497252)
• DEGRO expert consensus on ENI - Koerber et al., Strahlenther Onkol 2024 (PMID 38273135)
• De Meerleer et al. ENI review, Lancet Oncol 2021 (PMID 34339655)
• Patterns of failure - Singh/Murthy et al., Clin Oncol 2024 (PMID 38664178)
• RTOG 0924 interim results, ASTRO 2025 (no OS benefit in lower-risk patients)